AZ Alliance Bolsters Daiichi’s US Primary Care Presence
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is moving to shore up its generic-threatened primary care business in the US through a co-promotion deal with AstraZeneca for a novel constipation drug.